Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Mr. America?

  • News

Executive Summary

Pharmaceutical Research & Manufacturers of America President Alan Holmer will participate in a Nov. 19 press conference kicking off Miss America Katie Harman's "Breast Cancer in America: Caring Community-by-Community" 2002 platform. PhRMA will release its annual survey of research on medicines for women as part of the press event. The kick-off was originally planned as a Capitol Hill event to include the Oregon Congressional delegation: Harman was Miss Oregon and Holmer was on the staff of former Oregon Sen. Robert Packwood (R). The Capitol Hill event had to be postponed because of the anthrax scare....Rep. Waxman staff change: Tim Westmoreland, legislative assistant and counsel to Rep. Henry Waxman (D-Calif.), is taking a full-time teaching position at Georgetown Law in January...

Table

View full table

Tags:
Latest Headlines

Mismatch Between Growing Vaccine Pipeline and CDC’s ACIP Capacity

Keeping Track: Two Breakthrough Oncologics, Another Antibiotic Clear US FDA Along With Pfizer’s Hemophilia B Gene Therapy

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

See All
UsernamePublicRestriction

Register

PS038869

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By